GIP and hepatorenal syndrome: Of note, three of the peptides that received the green light in 2022 are considered first-in-class—namely, MounjaroTM (which activates glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), TerlivazTM (first-line treatment for hepatorenal syndrome (HRS)), and PluvictoTM (first targeted radioligand therapy (RLT)) [3].